OHSU Knight Cancer Institute News
The OHSU Knight Cancer Institute receives international, regional and local media coverage.
Breast cancer researcher receives $100,000 grant to develop postnatal pill
Pepper Schedin, Ph.D., a breast cancer researcher with the OHSU Knight Cancer Institute recently received a $100,000 grant from the Kay Yow Cancer Fund, in partnership with the Women’s Basketball Coaches Association and the V Foundation for Cancer Research. With the funding, Schedin will be able to investigate the impact of anti-inflammatory drugs, such as ibuprofen or aspirin, on the unique biology of women’s bodies post-pregnancy.
FEI, OHSU expand their partnership for high-powered microscopes
FEI Co., the Hillsboro, Ore.-based maker of electronic microscopes, expanded its partnership with OHSU and the OHSU Knight Cancer Institute. This expansion adds a new instrument, the FEI CorrSightTM, to the OHSU-FEI correlative light and electron microscopy suite, in the Living Lab for Cell Biology. This agreement that includes the installation of a complete correlative microscopy workflow that will help researchers better understand how cancer cells and other diseases develop in the body.
Sen. Wyden: Oregon on the leading edge in palliative care
U.S. Sen. Ron Wyden, in a keynote speech at the American Cancer Society Cancer Action Network’s forum on palliative care, said that Oregon is leading the way when it comes to palliative care. Along with Wyden, speakers at the event included Erik Fromme, M.D., M.C.R., FAAHPM, medical director of OHSU Palliative Service,and Susan Hedlund, M.S.W., L.C.S.W., O.S.W.-C, manager of patient and family support servicesfor the OHSU Knight Cancer Institute. Fromme and Hedlund shared their views on misconceptions surrounding and the importance of palliative care.
The Ford Family Foundation donates $5 million to Knight Cancer Challenge for rural outreach
The Ford Family Foundation has given $5 million to the OHSU Knight Cancer Institute, which counts toward the Knight Cancer Challenge, to expand prevention and care programs for rural Oregonians.
Brian Druker among five American winners of prestigious Hamdan Medical Award
Brian Druker, M.D., director of the OHSU Knight Cancer Institute, won the Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Research Excellence. Druker won the award for his breakthrough work on targeted cancer therapies, which produced a paradigm shift in the treatment of cancer.
Breast cancer inspires local musician to put on fundraising concert
Jenny Conlee, keyboard player for the Decemberists, was diagnosed with breast cancer in 2011 at the age of 38. That experience led her to put on a yearly event called Notes of Hope, which is aimed at cancer patients between the ages of 15 and 39. The event, which includes a mix of live music and storytelling, benefits the OHSU Knight Cancer Institute’s Adolescent and Young Adult Oncology Program.
OHSU Doctor Hopes Melanoma Registry Will Aid Education, Research
Doctors and patients gathered recently at OHSU for a conference on melanoma, to cover cutting-edge treatments for this deadly disease led by Sancy Leachman, M.D., director, OHSU Knight Cancer Institute Melanoma Program and chair, Department of Dermatology. Members of the Melanoma Community Registry, launched in May 2014 by the OHSU Knight Cancer Institute, gathered recently to learn about the disease, new treatments and research results. More than 3,000 patients, family members and friends have signed up for the registry to date.
Standard employees wear jeans, raise big bucks for cancer
Standard Insurance Co., through its 2014 Employee Giving Campaign, raised $534,000 for the Knight Cancer Challenge. More than 1,500 current and retired employees donated, exceeding expectations and more than doubling the original pledge amount.
Portland filmmaker explores healing through humor
Portland film student Ben Schorr’s documentary about how humor can help in coping with cancer features interviews with three people who share different perspectives, including Brian Druker, M.D., director of the OHSU Knight Cancer Institute. Schorr’s mother participated in Dr. Druker’s clinical trials that made Gleevec®, the first targeted cancer drug of its kind, a reality for patients.
OHSU scientist finds exercise stops or slows bone loss for cancer survivors
Kerri Winters-Stone, Ph.D., a researcher at the OHSU Knight Cancer Institute, studies the benefits of exercise and how it might help people cope with the aftermath of cancer treatment. Winters-Stone discussed what exercise could mean for cancer survivors.
High Desert conditions lead to high skin cancer rates
Oregon’s sunny High Desert region boasts some of the highest rates of skin cancer in the state. Sancy Leachman, M.D., Ph.D., head of melanoma research at the OHSU Knight Cancer Institute, weighed in on the conditions that lead to such high skin cancer rates and discusses which symptoms to watch for.
Aptose Biosciences Joins OHSU to Fight Deadly Form of Leukemia
Aptose Biosciences joined the Beat AML collaboration, led by researchers at the OHSU Knight Cancer Institute. The multi-institutional research initiative aims to find treatments for acute myeloid leukemia (AML).
Brian Druker joins Live Wire
OHSU Knight Cancer Institute Director Brian Druker, M.D., joined the season premiere of Live Wire, a Portland-based radio show that airs nationally. The show focused on trailblazers in their fields. Druker’s interview focused on his research that led to the once-a-day cancer pill Gleevec® and the plans he has to meet what he believes is most important unmet need in cancer care today.
Men, if you’re 50, it’s time for a prostate exam
Christopher Amling, M.D., urologic cancer specialist with the OHSU Knight Cancer Institute, discussed the importance of prostate exams, the pros and cons of the screening and when to have a conversation about the exam with a physician.
Columbia Sportswear chairwoman revealed as $100-million donor
The OHSU Knight Cancer Institute received in July 2014 a $100-million gift from Gert Boyle, the chairwoman of Columbia Sportswear. She initially made the donation anonymously but later publicly confirmed her identity to encourage others to give.
BioCentury: Transformative Medicine
Brian Druker, M.D., director of the OHSU Knight Cancer Institute, explained the science behind Gleevec and other targeted cancer drugs, which moved treatment from systemic and toxic therapies to life-saving approaches with specific targets.
Anonymous $100 Million Gift Moves OHSU Within $82 Million of Reaching $1 Billion Goal
The OHSU Knight Cancer Institute moved one step closer to meeting a spectacular fundraising goal when it received a $100 million gift from an anonymous donor.
When Unapproved Drugs are the Only Hope
Nathalie Traller was diagnosed in 2013 with a rare cancer that a new class of drugs may help combat. But, at 15 years old, she’s too young to qualify for the related clinical trials. Brian Druker, M.D., director of the OHSU Knight Cancer Institute and a major force behind development of the leukemia drug Gleevec, has adopted Nathalie’s case and is working with colleagues at the National Institutes of Health to explore possible options for her.
$100-Million Gift Pushes Oregon University to Brink of Securing $500-Million Match
Oregon Health & Science University received a $100-million anonymous gift, which became part of a $1 billion fundraising drive for the Knight Cancer Institute that got a large dose of urgency from Phil and Penny Knight’s pledge.
OHSU receives $100 million anonymous gift toward Knight Cancer Challenge
An anonymous donor gave $100 million to OHSU Knight Cancer Institute to help a fundraising challenge <link to www.onedown.org> ; the gift is one of the four largest pledges in OHSU’s history and is the largest private donation to the campaign to date.
Pete Julian's race isn't over, but the Oregon Project coach is kicking cancer
Pete Julian, now an assistant coach with the Nike Oregon Project distance runners training group, was at a loss following his 2008 cancer surgery. Diagnosed with GIST, his third gastrointestinal surgery was only partially successful, leaving him with at least three tumors. When Dr. Michael Heinrich put him on a targeted therapy that OHSU’s Brian Druker helped develop, his tumors vanished.
Private donors are playing an increasingly important role in the funding—and direction—of scientific research including at the OHSU Knight Cancer Institute.
How OHSU's Brian Druker Hopes to Cure Cancer
Brian Druker, M.D., director of OHSU’s Knight Cancer Institute, and OHSU President Joe Robertson, M.D., M.B.A., share insights on OHSU’s $200 million request for state support, the $1 billion Knight Cancer Challenge, and what OHSU will do with the billion dollars it is raising.
Growing Participation in Novartis' Signature Program Bodes Well for Novel PGx Signal Finding Approach
Drug maker Novartis last year launched the Signature Program, a drug trial series in which patients are enrolled in mutation-specific study protocols that emphasize molecular pathways over tumor sites or histology. Oregon Health & Science University is among the institutions leading the program.
OHSU's Knight Cancer Challenge bites off a $1M pledge
Willamette Dental Group announced in June 2014 that it will contribute $1 million to the Knight Cancer Challenge. The group dental practice will match all contributions to the challenge in the next year, and then President and Chief Executive Officer Dr. Eugene Skourtes will match the combined total.
“Be the Match” search for a bone marrow transplant
Cynthia Speckman, who was treated at the OHSU Knight Cancer Institute for chronic myeloid leukemia (CML ) appeared on KATU’s AM Northwest to talk about her diagnosis and search for a bone marrow transplant. She was joined by Be the Match spokesperson Kim Allen, who spoke about the organization and its efforts to help patients get marrow or cord blood transplants.
Local employees join Knight Cancer Challenge
Oregon companies have provided a huge boost to the $1 billion Knight Cancer Challenge since its announcement in September 2013. The Standard launched a year-long employee campaign in June 2014 to lend its support, vowing to raise more than $250,000 for the OHSU Knight Cancer Institute.
OHSU's Druker spells out plans for early cancer detection team
Brian Druker, M.D., director of the OHSU Knight Cancer Institute, told employees of The Standard that revolutionizing early cancer detection will be an integral part of Knight Cancer’s mission going forward. Druker was invited to speak to employees of The Standard as the company launched a campaign to raise funds for the $1 billion Knight Cancer Challenge.
FDA: Tanning lamps now considered 'high-risk'
In an effort to reduce rising rates of skin cancer linked to tanning devices, the FDA announced that tanning beds and sun lamps must carry new warnings. The OHSU Knight Cancer Institute increased its advocacy for such restrictions in 2013 when it, among other things, campaigned in support of Oregon passing a law restricting minors’ access to tanning beds.
OHSU doctor wages war on melanoma in Oregon
Sancy Leachman, M.D., Ph.D., who leads melanoma research at OHSU Knight Cancer Institute, recently launched a registry to create a network for advancing the treatment, prevention and detection of the disease.
OHSU reports $86 million in private donations for cancer research
Donors have given Oregon Health & Science University’s Knight Cancer Institute about $86 million within six months toward a $500 million goal. When combined with $200 million in bonding approved by state lawmakers, the institute is well past the halfway mark in meeting a $500 million challenge from Nike co-founder Phil Knight. More than 3,700 donations and pledges came from 47 states; Washington, D.C.; and Canada.
Who are the biggest givers? And where do they get the money?
Big philanthropy returned in 2013, keyed in part by Nike co-founder Phil Knight and his wife Penelope Knight. The Knights kick started the Knight Cancer Challenge with a $500 million pledge, provided OHSU can raise matching funds within two years.
Video - How OHSU's Brian Druker Hopes to Cure Cancer
Watch a video of Dr. Brian Druker at Willamette Week, discussing the opportunity to cure cancer with a $1.2 billion investment from private philanthropy as part of the Knight Cancer Challenge and state infrastructure support.
Drug May Extend Survival for Men With Advanced Prostate Cancer
A recently released study suggests that a new hormone therapy may increase survival for men with advanced prostate cancer. HealthDay speaks with the Knight Cancer Institute’s deputy director, Tomasz Beer, M.D. about the implications for patients.
How OHSU's Brian Druker Hopes to Cure Cancer
OHSU President Joe Robertson and Dr. Brian Druker sit in Willamette Week’s “Hot Seat” and answer questions about the Knight Cancer Challenge and Oregon’s opportunity to end cancer as we know it.
Oregon could sell $200 million in bonds for Phil and Penny Knight's $1 billion challenge for OHSU cancer research
Building on a record of success in partnerships, the Oregonian reports on $200 million in capital construction bonding OHSU is requesting for critical infrastructure to support cancer research and patient care/clinical trials.
The Knight Cancer Challenge is unprecedented for any fundraising campaign. It has the potential to transform philanthropy in Oregon and around the world.
As featured in:
Billion Dollar Knight Cancer Challenge
Dr. Brian Druker, talks about a billion research dollars.
Learn more about OHSU Knight Cancer Institute from these sources:
Smithsonian on Brian Druker, M.D., director of the OHSU Knight Cancer Institute
New York Times on Brian Druker’s stance on cancer drug prices
New England Journal of Medicine documentary on Brian Druker’s impact on cancer research and treatment
Wall Street Journal review of book that chronicles the history of Brian Druker’s cancer research breakthrough
Wall Street Journal on Beat AML collaboration
Wall Street Journal on program for young adults with cancer
Portland Monthly on the OHSU Knight Cancer Institute’s cancer research vision
Intel Corporation’s president’s speech including segment on OHSU-Intel collaboration in cancer research
The Oregonian on prostate cancer Dream Team
The Oregonian on breast cancer researcher Lisa Coussens
New York Times and Joe Gray
The Oregonian on the OHSU Knight Cancer Institute’s strategic vision
The Oregonian on the Knight Diagnostic Laboratories
Healthy Body, Healthy Mind on PBS, Treatment of Chronic Myeloid Leukemia
Healthy Body, Healthy Mind on PBS, Treatment of Gastrointestinal Stromal Tumor